Mammotome Unveils Revolutionary Vacuum-Assisted Breast Biopsy System for MRI Rooms

Mammotome Introduces Groundbreaking Biopsy Technology

Mammotome, a subsidiary of Danaher Corporation, has recently launched its latest innovation, the Mammotome Prima™ MR Dual Vacuum-Assisted Breast Biopsy System. This cutting-edge technology marks a significant milestone in the medical field as it is the first system designed to be used directly in magnetic resonance imaging (MRI) rooms, providing real-time convenience and efficiency for healthcare professionals and enhancing patient care.

The Mammotome Prima™ MR system aims to simplify existing biopsy procedures through its intuitive design and enhanced functionalities. Unlike previous systems, this revolutionary approach allows direct placement of the biopsy device within the MRI examination room, facilitating better communication among clinical teams. Scott Treml, Vice President and General Manager of Mammotome, emphasized that this product aims to elevate breast care standards, significantly impacting the comfort and experience of patients undergoing such procedures.

Enhanced Features for Improved Outcomes

The Mammotome Prima™ MR system offers several advantages that stand out in comparison to existing biopsy systems. One notable feature is its ability to collect larger tissue samples, made possible by stronger vacuum pressure and an 8-gauge needle. The device's performance is enhanced by a 75% reduction in tubing complexity compared to competitors, which subsequently speeds up setup time, eases cleaning protocols, and reduces hazardous biological waste.

Additionally, the user-friendly touch interface allows for convenient adjustments regarding the sampling aperture size and vacuum strength, further streamlining the overall workflow for physicians. Such specifications ultimately empower doctors to focus on delivering safe, precise, and compassionate care, resulting in a better patient experience overall.

Clinically Proven Effectiveness

Clinical studies highlight the Mammotome Prima™ MR system's effectiveness. Laboratory tests showed an impressive 78.6% increase in average sample weight compared to other systems in the same category, illustrating its superior capabilities. As healthcare professionals increasingly prioritize the quality and accuracy of diagnostic procedures, the Mammotome Prima™ MR serves as an essential tool in achieving these high standards.

Currently, the system has achieved the CE mark and initial procedures are being performed in select European countries. The official debut of this innovative device is set for March at the annual European Congress of Radiology (ECR). With plans for expansion into additional global markets by the end of 2026, Mammotome aims to provide even wider access to this groundbreaking solution.

Commitment to Advancement in Breast Care

Mammotome's continuous commitment to pushing the boundaries of breast care solutions drives its innovation initiatives. The company believes that integrating advanced technology with compassionate care is vital in meeting the diverse needs of healthcare providers and patients alike. By offering comprehensive product ranges and educational resources, Mammotome ensures that physicians and their patients are well-prepared throughout the biopsy process.

Based in Cincinnati, Ohio, Mammotome has been a part of the Danaher Corporation since 2014, and its products are now available in over 45 countries worldwide. The introduction of the Mammotome Prima™ MR is not just a product launch; it is a step towards a future where breast care is more accessible, efficient, and patient-centered.

For further information, visit the official Mammotome website to learn more about this innovative technology and the company’s mission to improve breast health care on a global scale.